Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 46
Filtrar
1.
Eur Rev Med Pharmacol Sci ; 28(6): 2396-2402, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38567602

RESUMEN

OBJECTIVE: This study investigates the incidence of urinary incontinence following transurethral thulium laser prostatectomy with three different prostate apex disconnection techniques: semi-separation, pre-separation, and post-separation. The findings aim to provide references for clinical treatment. PATIENTS AND METHODS: A retrospective analysis was conducted on 74 patients treated with transurethral thulium laser prostatectomy for prostatic hyperplasia from April 2022 to March 2023. Complete clinical and follow-up data were available for 52 patients. Clinical and follow-up data were collected for these patients. A comparison was made of urinary incontinence following the three different types of prostate apex disconnection in transurethral thulium laser prostatectomy. RESULTS: In this study, the immediate postoperative urinary incontinence rate for transurethral thulium laser prostatectomy was 9.62% (5/52), the short-term incontinence rate was 11.54% (5/52), and the long-term incontinence rate was 9.62% (5/52). The immediate postoperative incontinence rates for semi-separation, pre-separation, and post- separation were 8.33% (1/12), 8.33% (2/24), and 12.5% (2/16), respectively. The short-term incontinence rates for semi-separation, pre-separation, and post-separation were 8.33% (1/12), 8.33% (2/24), and 18.75% (3/16), respectively. The long-term incontinence rates for semi-separation, pre-separation, and post-separation were 8.33% (1/12), 8.33% (2/24), and 12.5% (2/16), respectively. CONCLUSIONS: The incidence of urinary incontinence following transurethral thulium laser prostatectomy was lower with semi-separation and pre-separation compared to post-separation.


Asunto(s)
Terapia por Láser , Hiperplasia Prostática , Resección Transuretral de la Próstata , Incontinencia Urinaria , Masculino , Humanos , Próstata , Tulio/uso terapéutico , Estudios Retrospectivos , Resultado del Tratamiento , Resección Transuretral de la Próstata/efectos adversos , Terapia por Láser/efectos adversos , Terapia por Láser/métodos , Hiperplasia Prostática/cirugía , Hiperplasia Prostática/tratamiento farmacológico , Incontinencia Urinaria/epidemiología , Incontinencia Urinaria/etiología , Rayos Láser , Prostatectomía/efectos adversos , Prostatectomía/métodos
2.
Eur Rev Med Pharmacol Sci ; 27(24): 11913-11922, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38164855

RESUMEN

OBJECTIVE: This study aims to explore the risk factors for stone remnants and recurrence after lateral decubitus percutaneous nephrolithotomy (PCNL), providing insights to enhance the stone-free rate and reduce the stone recurrence rate. PATIENTS AND METHODS: A retrospective analysis was conducted on 356 patients with renal or upper ureteral stones who underwent lateral decubitus PCNL from January 2015 to August 2022. Among them, 271 patients had complete clinical and follow-up data. General clinical information, perioperative data, and follow-up data were collected. Univariate and multivariate logistic regression analyses were performed to identify risk factors for stone remnants and recurrence after lateral decubitus PCNL. RESULTS: The stone-free rate after lateral decubitus PCNL was 88.6% (195/271), and the stone recurrence rate within three years was 28.1% (76/271). Stone size (p<0.001) and stone co-infection (p=0.047) were identified as independent risk factors for stone remnants after lateral decubitus PCNL. Multiple stones (p=0.003) were an independent risk factor for stone recurrence after lateral decubitus PCNL. CONCLUSIONS: Stone size and stone co-infection are independent risk factors for stone remnants after lateral decubitus PCNL. Multiple stones are an independent risk factor for stone recurrence after lateral decubitus PCNL.


Asunto(s)
Coinfección , Cálculos Renales , Nefrolitotomía Percutánea , Humanos , Nefrolitotomía Percutánea/efectos adversos , Cálculos Renales/cirugía , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento
3.
Eur Rev Med Pharmacol Sci ; 25(6): 2458, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33829421

RESUMEN

The article "Circ_0001982 accelerates the progression of colorectal cancer via sponging microRNA-144, by Q. Deng, C.-J. Wang, R. Hao, Q.-Y. Yang, published in Eur Rev Med Pharmacol Sci 2020; 24 (4): 1755-1762-DOI: 10.26355/eurrev_202002_20352-PMID: 32141543" has been withdrawn from the authors due to some inaccuracies about pictures and data (Figures 2C and 2D need to be further confirmed). The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/20352.

4.
Eur Rev Med Pharmacol Sci ; 24(22): 11496-11508, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33275216

RESUMEN

OBJECTIVE: To explore the connections between hair cells and spiral ganglion neurons (SGNs) during the development of the C57BL/6 mouse inner ear. MATERIALS AND METHODS: The specimens of C57BL/6 mouse inner ear, from E15 (embryo day 15) to adult mouse, were collected; immunohistochemistry was employed to explore the frozen sections of specimens. RESULTS: The development of cochlea starts sequentially from the basal turn to the apex turn. Morphological development of SGNs occurs mainly from E16 to P12 (postnatal day 12). Hair cells appear from E18 to P12, and inner hair cells (IHCs) develop earlier than outer hair cells (OHCs). The connections between hair cells and SGNs begin to develop during E18-P1, morphologically resemble mature synapses during P8-P12, and completely mature in adult mice. CONCLUSIONS: The genesis of auditory ribbon synapse occurs from E18 to P1. Synchronized with the development of SGNs and hair cells, the functional filaments remain connected to hair cells, while the spare ones get disconnected from the surface of hair cells. Connections between SGN nerve filaments and IHCs occur earlier than those between SGN nerve filaments and OHCs.


Asunto(s)
Oído Interno/crecimiento & desarrollo , Células Ciliadas Auditivas Internas/metabolismo , Células Ciliadas Auditivas Externas/metabolismo , Neuronas/metabolismo , Ganglio Espiral de la Cóclea/metabolismo , Sinapsis/metabolismo , Animales , Oído Interno/citología , Oído Interno/metabolismo , Femenino , Células Ciliadas Auditivas Internas/citología , Células Ciliadas Auditivas Externas/citología , Masculino , Ratones , Ratones Endogámicos C57BL , Neuronas/citología , Ganglio Espiral de la Cóclea/citología
5.
Eur Rev Med Pharmacol Sci ; 24(4): 1755-1762, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32141543

RESUMEN

OBJECTIVE: The aim of this study was to uncover the expression pattern and biological function of circ_0001982 in the progression of colorectal cancer (CRC). PATIENTS AND METHODS: Relative expression level of circ_0001982 in 66 paired CRC tissues and adjacent normal tissues was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The association between circ_0001982 level and clinical indexes of CRC patients was assessed. The effect of circ_0001982 on cellular behaviors of HT29 and HCT-116 cells was evaluated in vitro. Dual-Luciferase reporter gene assay was conducted to verify the binding relation between circ_0001982 and microRNA-144. Finally, rescue experiments were performed to assess the role of the circ_0001982/microRNA-144 axis in mediating the progression of CRC. RESULTS: Circ_0001982 was significantly up-regulated in CRC tissues when compared with adjacent normal ones. CRC patients with a high expression level of circ_0001982 showed a significantly higher rate of distant metastasis and worse survival. Knockdown of circ_0001982 remarkably attenuated the proliferative, migratory, and invasive capacities of HCT-116 cells. However, opposite results were observed after the overexpression of circ_0001982 in HT29 cells. MicroRNA-144 was verified as a target gene of circ_0001982, which could be negatively regulated by circ_0001982. Furthermore, microRNA-144 was capable of reversing the regulatory effect of circ_0001982 on the proliferative, migratory, and invasive capacities of CRC cells. CONCLUSIONS: Up-regulated circ_0001982 was closely related to distant metastasis and poor prognosis of CRC. In addition, circ_0001982 attenuated the progression of CRC by negatively regulating microRNA-144.


Asunto(s)
Neoplasias Colorrectales/genética , Neoplasias Colorrectales/patología , MicroARNs/genética , ARN Circular/genética , Línea Celular , Movimiento Celular , Proliferación Celular , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad
6.
Eur Rev Med Pharmacol Sci ; 23(1): 87-95, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30657550

RESUMEN

OBJECTIVE: To investigate the effects of miR-32-5p on the biological behaviors of cervical cancer (CCa), the relevant mechanism was studied in CCa cell lines (HeLa) in vitro. PATIENTS AND METHODS: The expression level of miR-32-5p was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). TargetScan, miRDB, microRNA databases and Luciferase method were conducted to predict and validate the target gene of miR-32-5p; the effects of miR-32-5p on cell proliferation, clone formation, invasion and migration capacity were analyzed in vitro study. RESULTS: We found miR-32-5p to be significantly inhibited in CCa tissues and cells. Bioinformatics approach together with Luciferase method screened Homeobox B8 (HOXB8) as a downstream regulatory target of miR-32-5p. Besides, HOXB8 was incredibly high expression in CCa tissues and cells. After transfection in HeLa cells by miR-32-5p mimics, HOXB8 expression was indicated to be negatively correlated with miR-32-5p both in qRT-PCR and Western blot (WB) assays. The subsequent experiments showed that decreased expression of HOXB8 resulting from up-regulation of miR-32-5p could weaken the cell proliferation, clone formation, invasion and migration ability of HeLa cells. CONCLUSIONS: MiR-32-5p could inhibit the cellular malignant behavior through regulating the expression of HOXB8 in HeLa cells. We provide a new clue for the study of molecular mechanisms of CCa. MiR-32-5p/HOXB8 axis might serve as potential target for the clinical diagnosis and treatment of CCa.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Cuello del Útero/patología , Proteínas de Homeodominio/genética , MicroARNs/metabolismo , Neoplasias del Cuello Uterino/genética , Regiones no Traducidas 3' , Apoptosis/genética , Movimiento Celular , Proliferación Celular , Cuello del Útero/cirugía , Regulación hacia Abajo , Femenino , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Células HEK293 , Células HeLa , Humanos , Histerectomía , Invasividad Neoplásica/genética , Regulación hacia Arriba , Neoplasias del Cuello Uterino/diagnóstico , Neoplasias del Cuello Uterino/patología , Neoplasias del Cuello Uterino/cirugía
7.
Eur Rev Med Pharmacol Sci ; 22(21): 7371-7378, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30468483

RESUMEN

OBJECTIVE: To investigate the role of miR-10b in the proliferation and apoptosis of acute myeloid leukemia (AML), and to explore the underlying mechanism. PATIENTS AND METHODS: The expression level of miR-10b in clinical AML cases and cell lines was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The interaction between miR-10b and homeobox D10 (HOXD10) was confirmed by qRT-PCR, Western blotting and Luciferase assay. The effect of miR-10b on biological functions of AML cell line (HL60) was analyzed in vitro. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay and colony formation assay were used to detect the proliferation and colony formation ability of AML cells, respectively. Meanwhile, flow cytometry and TUNEL staining were applied to measure cell cycle and apoptosis of AML cells, respectively. RESULTS: miR-10b was significantly up-regulated in AML cases and cell lines. The potential target genes of miR-10b were analyzed by three public databases. Results showed that HOXD10 was a direct target of miR-10b. QRT-PCR, Western blotting and luciferase assay confirmed the regulatory effect of miR-10b on HOXD10. Overexpression of miR-10b accelerated the proliferation and colony formation ability of AML cells. Meanwhile, miR-10b overexpression decreased the percentage of AML cells in the G0/G1 phase when compared with S phase, and suppressed the apoptosis of AML cells. However, the addition of HOXD10 could reverse the effects of miR-10b. CONCLUSIONS: MiR-10b could regulate the proliferation, colony formation, cell cycle and apoptosis of AML cells through targeting HOXD10, indicating that miR-10b might be a potential therapeutic target for the treatment of AML.


Asunto(s)
Apoptosis/genética , Apoptosis/fisiología , Proliferación Celular , Proteínas de Homeodominio/genética , MicroARNs/genética , Factores de Transcripción/genética , Ciclo Celular/genética , Ciclo Celular/fisiología , Niño , Marcación de Gen , Células HL-60 , Humanos , Ensayo de Tumor de Célula Madre , Regulación hacia Arriba/genética
8.
Eur Rev Med Pharmacol Sci ; 22(14): 4604-4610, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-30058697

RESUMEN

OBJECTIVE: Acute kidney injury (AKI) is common in critically ill patients, and sepsis patients with AKI had a higher mortality rate. The aim of the present study was to determine the potential value of urinary miR-26b in the diagnosis of sepsis-associated AKI. PATIENTS AND METHODS: Urinary samples were collected from a cohort of 155 sepsis patients (68 AKI patients and 87 non-AKI patients) and 57 patients with non-infectious systemic inflammatory response syndrome (SIRS). The expression levels of urinary miR-26b were measured by RT-qPCR analysis. ROC curve analysis was performed to determine the diagnostic value. Pearson correlation analysis was performed to assess the levels of urinary miR-26b and several clinical parameters. Kaplan-Meier curves were plotted to show the impact of urinary miR-26b on the 28-day survival. RESULTS: Significantly increased urinary miR-26b levels were found in patients with sepsis-associated AKI. Urinary miR-26b had a sensitivity of 90.8% and specificity of 75.0% for distinguishing between AKI sepsis and non-AKI sepsis. Urinary miR-26b levels were closely correlated with clinical parameters reflecting the severity of the disease. Kaplan-Meier analysis revealed that sepsis patients with high urinary miR-26b levels had an elevated mortality rate. CONCLUSIONS: Taken together, these findings suggested that urinary miR-26b might be utilized as a potential biomarker for sepsis-associated AKI.


Asunto(s)
Lesión Renal Aguda/diagnóstico , Biomarcadores/orina , MicroARNs/orina , Sepsis/patología , Lesión Renal Aguda/etiología , Adulto , Anciano , Área Bajo la Curva , Proteína C-Reactiva/análisis , China , Estudios de Cohortes , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Curva ROC , Sensibilidad y Especificidad , Sepsis/complicaciones , Sepsis/mortalidad
9.
Eur Rev Med Pharmacol Sci ; 22(10): 3166-3172, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29863262

RESUMEN

OBJECTIVE: The collateral circulation development is considered as a compensatory inherent mechanism to restore damaged blood perfusion after ischemia. We aimed to detect the collateral flow and the mean blood-flow velocities (mBFVs) level in the basilar trunk during or after cerebral hypoxia-ischemia in the mice brain and explore the effect of neuronal nitric oxide synthase (nNOS) inhibition on the collateral flow. MATERIALS AND METHODS: C57BL/6J mice and the nNOS knockout (KO) mice were randomly divided into a sham-operated group (control) and the hypoxia-ischemia (HI) groups that were treated with the phosphate buffered solution (PBS) control or 7-nitroindazole (7-NI). Cortexes were harvested after the HI treatment for analysis of nNOS expression using Western blot and reverse transcription-polymerase chain reaction (RT-PCR). Ultrasound imaging experiments were performed to detect the collateral flow and the mBFVs level in the basilar trunk. RESULTS: After cerebral HI, the cortical nNOS mRNA and protein levels increased markedly compared with the sham-operated control mice. Besides, 7-NI treatment had no effect on the blood flow in the sham-operated control mice. What's more, either the 7-NI pretreatment or the nNOS gene knockdown before the HI procedure could attenuate the brain injury by the increased collateral flow and the decreased mBFVs level in the basilar trunk. CONCLUSIONS: nNOS inhibition protected hypoxic-ischemic-induced mice brain damage by the increased collateral flow and the decreased mBFVs level in the basilar trunk. Therefore, the 7-NI administration may have potential utility for the treatment of HI injury in human beings.


Asunto(s)
Circulación Colateral/fisiología , Hipoxia-Isquemia Encefálica/fisiopatología , Óxido Nítrico Sintasa de Tipo I/fisiología , Animales , Lesiones Encefálicas/metabolismo , Corteza Cerebral/metabolismo , Circulación Colateral/efectos de los fármacos , Modelos Animales de Enfermedad , Hemodinámica , Hipoxia-Isquemia Encefálica/metabolismo , Indazoles/farmacología , Masculino , Ratones , Ratones Noqueados , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo I/biosíntesis , Óxido Nítrico Sintasa de Tipo I/genética
10.
Bone Joint J ; 99-B(12): 1643-1650, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29212688

RESUMEN

AIMS: We conducted a study to identify factors that are prognostic of the outcome of extracorporeal shockwave therapy (ESWT) for calcific tendinitis of the shoulder. PATIENTS AND METHODS: Since 1998, patients with symptomatic calcific tendinitis of the rotator cuff have been treated with ESWT using an electrohydraulic mode shockwave device. One year after ESWT, patients were grouped according to the level of resorption of calcification. RESULTS: Of 241 symptomatic shoulders, complete resorption (CR) of calcification occurred in 134 (CR group). The remaining 107 shoulders had incomplete resorption (ICR) (ICR group). Gartner type I calcification was most common (64.5%) in the ICR group. The mean duration of symptoms before ESWT was significantly longer in the ICR group. Overall, 81% of the CR group and 23.4% of the ICR group were symptom free. There was a strong relationship between subsidence of symptoms and remission of calcification. Poor prognosis was significantly related to Gartner type I calcification, calcification extent > 15 mm and duration of symptoms > 11 months. CONCLUSION: Patients with calcific tendinitis of the shoulder who have the factors identified for a poor outcome after ESWT should undergo a different procedure. Cite this article: Bone Joint J 2017;99-B:1643-50.


Asunto(s)
Calcinosis/terapia , Tratamiento con Ondas de Choque Extracorpóreas , Manguito de los Rotadores , Dolor de Hombro/terapia , Hombro , Tendinopatía/terapia , Adulto , Anciano , Calcinosis/diagnóstico por imagen , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Rango del Movimiento Articular , Manguito de los Rotadores/diagnóstico por imagen , Hombro/diagnóstico por imagen , Dolor de Hombro/etiología , Tendinopatía/diagnóstico por imagen , Resultado del Tratamiento
11.
Clin. transl. oncol. (Print) ; 19(10): 1260-1267, oct. 2017. tab, graf
Artículo en Inglés | IBECS | ID: ibc-166160

RESUMEN

Purpose. The significance of the Risk of Ovarian Malignancy Algorithm (ROMA) in differentiating benign and malignant ovarian lesions has been evidenced. In our clinical work, we found that advanced ovarian cancer were accompanied commonly with high ROMA scores. Thus, this study aimed to clarify the performance of ROMA in different disease stage of epithelial ovarian cancer (EOC) prior to surgery. Methods. Carbohydrate antigen (CA125) and human epididymis protein 4 (HE4) levels and ROMA scores in 221 patients with FIGO stage I, II or III/IV stage EOC were analyzed. The positive rates of CA125, HE4 and ROMA at each disease stage were calculated. Their cutoff values, sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) for distinguishing patients with FIGO stage I/II from those with FIGO stage III/IV were estimated via ROC curves. Results. Serum CA125 and HE4 levels and ROMA scores rose significantly with advancing stage. ROMA and CA125 were significantly elevated more frequently in comparing with HE4 in EOC patients at with the same stage. Based on ROC curves, the cutoff values for FIGO stage III/IV EOC were 110 IU/mL, 126 pmol/L, 78 and 68% for CA125, HE4, premenopausal and postmenopausal ROMA, respectively. ROMA was the strongest predictor of FIGO stage, with the highest specificity, accuracy, and PPV, which were 84.4, 82.5, and 87.0% for postmenopausal patients, 89.3, 85.6, and 74.3% for premenopausal patients. Conclusions. Our data suggest high ROMA scores correlated with advanced ovarian cancer prior to surgery. These observations suggest potential utility of ROMA in the comprehensively preoperative evaluation of EOC patients (AU)


No disponible


Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Neoplasias Ováricas/epidemiología , Estadificación de Neoplasias/clasificación , Epidídimo/patología , Menopausia , Posmenopausia , Algoritmos , Biomarcadores/análisis , Antígeno Ca-125/administración & dosificación , Antígeno Ca-125/análisis , Estadísticas no Paramétricas
12.
Gene Ther ; 24(7): 392-398, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28436941

RESUMEN

This study aimed to investigate the correlation between INSR gene polymorphisms on platinum-based chemotherapy sensitivity and prognosis in epithelial ovarian cancer (EOC). A total of 339 EOC patients receiving postoperative chemotherapy were recruited for the study. Tag single-nucleotide polymorphism of INSR gene was screened from HapMap combined with available literature. Frequency distribution of genotypes and alleles in INSR gene was sequenced by ABI3100-Avant. Compared with CC+GC genotype, INSR rs2252673 GG genotype and rs3745546 CC genotype showed less platinum-based chemotherapy sensitivity in EOC patients (odds ratio (OR)=0.269, 95% confidence interval (CI)=0.159~0.456; OR=0.445, 95% CI=0.214~0.926, respectively), as well as serous EOC patients (OR=0.083, 95% CI=0.024~0.278; OR=0.235, 95%CI=0.053~1.041, respectively). The clinical characteristics including age, clinical stage, histological grade and residual lesion size were significantly related with chemosensitivity to platinum drugs and mortality in EOC patients. According to Kaplan-Meier curve, compared with CC+GC genotype, rs2252673 GG genotype showed significantly decreased survival rate in EOC patients (P<0.05). Cox regression model indicated that rs2252673, age and clinical stage were independent risk factors for the prognosis in EOC (all P<0.05). These findings indicate that INSR rs2252673 and rs3745546 polymorphisms were associated with sensitivity to platinum-based chemotherapy in EOC patients and rs2252673 polymorphism may be an independent risk factor for EOC prognosis.


Asunto(s)
Antígenos CD/genética , Antineoplásicos/uso terapéutico , Neoplasias Glandulares y Epiteliales/genética , Neoplasias Ováricas/genética , Compuestos de Platino/uso terapéutico , Polimorfismo de Nucleótido Simple , Receptor de Insulina/genética , Carcinoma Epitelial de Ovario , Femenino , Humanos , Persona de Mediana Edad , Neoplasias Glandulares y Epiteliales/tratamiento farmacológico , Neoplasias Glandulares y Epiteliales/patología , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/patología
13.
Clin Transl Oncol ; 19(10): 1260-1267, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28444641

RESUMEN

PURPOSE: The significance of the Risk of Ovarian Malignancy Algorithm (ROMA) in differentiating benign and malignant ovarian lesions has been evidenced. In our clinical work, we found that advanced ovarian cancer were accompanied commonly with high ROMA scores. Thus, this study aimed to clarify the performance of ROMA in different disease stage of epithelial ovarian cancer (EOC) prior to surgery. METHODS: Carbohydrate antigen (CA125) and human epididymis protein 4 (HE4) levels and ROMA scores in 221 patients with FIGO stage I, II or III/IV stage EOC were analyzed. The positive rates of CA125, HE4 and ROMA at each disease stage were calculated. Their cutoff values, sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) for distinguishing patients with FIGO stage I/II from those with FIGO stage III/IV were estimated via ROC curves. RESULTS: Serum CA125 and HE4 levels and ROMA scores rose significantly with advancing stage. ROMA and CA125 were significantly elevated more frequently in comparing with HE4 in EOC patients at with the same stage. Based on ROC curves, the cutoff values for FIGO stage III/IV EOC were 110 IU/mL, 126 pmol/L, 78 and 68% for CA125, HE4, premenopausal and postmenopausal ROMA, respectively. ROMA was the strongest predictor of FIGO stage, with the highest specificity, accuracy, and PPV, which were 84.4, 82.5, and 87.0% for postmenopausal patients, 89.3, 85.6, and 74.3% for premenopausal patients. CONCLUSIONS: Our data suggest high ROMA scores correlated with advanced ovarian cancer prior to surgery. These observations suggest potential utility of ROMA in the comprehensively preoperative evaluation of EOC patients.


Asunto(s)
Adenocarcinoma de Células Claras/patología , Adenocarcinoma Mucinoso/patología , Biomarcadores de Tumor/sangre , Cistadenocarcinoma Seroso/patología , Neoplasias Endometriales/patología , Neoplasias Ováricas/patología , Adenocarcinoma de Células Claras/sangre , Adenocarcinoma de Células Claras/cirugía , Adenocarcinoma Mucinoso/sangre , Adenocarcinoma Mucinoso/cirugía , Adulto , Anciano , Algoritmos , Antígeno Ca-125/sangre , Cistadenocarcinoma Seroso/sangre , Cistadenocarcinoma Seroso/cirugía , Neoplasias Endometriales/sangre , Neoplasias Endometriales/cirugía , Femenino , Estudios de Seguimiento , Humanos , Proteínas de la Membrana/sangre , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/sangre , Neoplasias Ováricas/cirugía , Cuidados Preoperatorios , Proteínas/análisis , Curva ROC , Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAP , Adulto Joven
15.
Clin. transl. oncol. (Print) ; 18(5): 507-514, mayo 2016. ilus, graf
Artículo en Inglés | IBECS | ID: ibc-151184

RESUMEN

Purpose: Gastric cancer (GC) is one of the leading causes of cancer mortality worldwide. Although therapeutic strategies for GC have improved, the prognosis for advanced GC remains poor. Herein, the present study sought to design a personalized cancer therapy specific to a stage III GC patient. Methods: The tumor was surgically removed and was used to establish a patient-derived tumor xenograft (PDTX) model utilizing nude mice. Various molecular-targeted anticancer treatments were tested in the study, including control (no treatment), bevacizumab, cetuximab, bevacizumab + cetuximab, trastuzumab, and trastuzumab + cetuximab. Results: Trastuzumab + cetuximab treatment exhibited the best antitumor growth effect, followed by trastuzumab, bevacizumab + cetuximab, cetuximab, and bevacizumab. Similarly, trastuzumab + cetuximab was also the most effective treatment at inducing apoptosis and cell cycle arrest in primary cultures of the patient’s gastric cancer cells. Among all treatments tested in the study, trastuzumab + cetuximab showed the most profound effect in reducing the protein expression of proliferation and metastatic markers (VEGF, MMP-7, EGFT, Ki-67 and, PCNA) in tumors obtained from PDTX models, which may be the mechanism underlying the profound antitumor growth effect exerted by trastuzumab + cetuximab. Conclusions: The data indicate that trastuzumab + cetuximab combinational therapy should be the most effective antitumor growth therapy for the GC patient whom we took the cancer cells from (AU)


No disponible


Asunto(s)
Humanos , Masculino , Femenino , Neoplasias Gástricas/tratamiento farmacológico , Terapia Combinada/instrumentación , Terapia Combinada/métodos , Terapia Combinada , Quimioterapia Combinada/instrumentación , Quimioterapia Combinada/métodos , Cetuximab/uso terapéutico , Trastuzumab/uso terapéutico , Pronóstico , Neoplasias Esofágicas/complicaciones , Neoplasias Esofágicas/tratamiento farmacológico , Carcinoma de Células Escamosas/tratamiento farmacológico
16.
Acta Anaesthesiol Scand ; 60(6): 780-9, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26822955

RESUMEN

BACKGROUND: Effects of low tidal volume (LTV) ventilation preconditioning in endotoxin-induced acute lung injury (ALI) have not been studied. We investigated the effect of LTV ventilation pre-treatment on ALI induced by lipopolysaccharide (LPS) in rats. METHODS: Male Sprague-Dawley rats were assigned to four groups (n = 8 each): (1) sham rats injected (i.p.) with 0.9% (physiologic) saline; sham rats pre-treated with tidal volume 6 ml/kg ventilation for 1 h followed by injection (i.p.) of physiologic saline (mechanical ventilation; MV-saline group); (2) LPS group (rats injected with LPS (i.p.); rats pre-treated with tidal volume 6 ml/kg ventilation for 1 h before injection (i.p.) with LPS (MV-LPS group). Animals were observed for 6 h. ALI extent was evaluated by lung wet-to-dry ratio, Evans Blue Dye extravasation, and histologic examination. We measured levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1ß, and IL-6. Apoptotic index (AI) and the expression of pulmonary RhoA, ROCK2 mRNA, and ROCK1 protein in lung alveolar cells was determined. RESULTS: Lipopolysaccharide caused severe ALI, as evidenced by increases in ALI extent, impairment of pulmonary functions, and increases in pulmonary levels of TNF-α, IL-1ß, IL-6, and AI. LTV ventilation preconditioning mitigated LPS-induced increases in release of pulmonary pro-inflammatory cytokines and AI of alveolar cells. Expression of pulmonary RhoA, ROCK2 mRNA, and ROCK1 protein was upregulated by LPS and reduced by LTV ventilation pre-treatment. CONCLUSION: Low tidal volume ventilation preconditioning can attenuate release of pulmonary pro-inflammatory cytokines and decrease the AI induced by severe sepsis. Early protection seems to be mediated partly through inhibition of activation of a Rho pathway.


Asunto(s)
Lesión Pulmonar Aguda/inducido químicamente , Volumen de Ventilación Pulmonar , Animales , Lipopolisacáridos , Pulmón/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/genética
17.
Eur Rev Med Pharmacol Sci ; 19(21): 4004-11, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26592821

RESUMEN

OBJECTIVE: Multiple sclerosis (MS) is an autoimmune disease that results with a damaged myelin sheath as a result, there is an impairment of nerve impulse conduction. The medication for MS is able to delay its progression, but complete recovery is impossible. Recent studies with neural stem cells have promising results in treating as well as to recover the damaged nerves, but research on in vivo model system is limited in this aspect. MATERIALS AND METHODS: Here we are able to successfully establish an MS mice model by injecting with myelin basic protein and we studied the neural stem cell response in supplement with vitamin D. RESULTS: Through histology we provide strong evidence that the MS pathogenesis is reverted on response to vitamin D. We also identified through immunohistochemistry and western blotting that the vitamin D has the ability to trigger neural stem cells, and thereby it assist in recovery from MS. Further, their roles in preventing as well as delaying the MS development are also proven. The role of vitamin D has also cross checked with the help of tunnel assay. CONCLUSIONS: Overall, our results conclude that the lesion associated apoptotic signals are reduced on administrated with vitamin D. The present data help to design a new therapeutic intervention to cure MS.


Asunto(s)
Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Esclerosis Múltiple/tratamiento farmacológico , Células-Madre Neurales/efectos de los fármacos , Vitamina D/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/patología , Suplementos Dietéticos , Regulación hacia Abajo , Encefalomielitis Autoinmune Experimental/patología , Femenino , Ratones , Esclerosis Múltiple/patología , Células-Madre Neurales/patología , Células-Madre Neurales/fisiología , Vitamina D/farmacología
18.
Clin Radiol ; 69(12): e505-11, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25248288

RESUMEN

AIM: To evaluate the early success of transarterial embolization (TAE) in patients with traumatic liver haemorrhage and to determine independent factors for its failure. MATERIALS AND METHODS: From January 2009 to December 2012, TAE was performed in 48 patients for traumatic liver haemorrhage. Their medical charts were reviewed for demographic information, pre-TAE vital signs and laboratory data, injury grade, type of contrast medium extravasation (CME) at CT, angiography findings, and early failure. "Early failure" was defined as the need for repeated TAE or a laparotomy for hepatic haemorrhage within 4 days after TAE. Variables were compared between the early success and early failure groups. Variables with univariate significance were also analysed using multivariate logistic regression for predictors of early failure. RESULTS: Among 48 liver TAE cases, nine (18.8%) were early failures due to liver haemorrhage. Early failure was associated with injury grade (p = 0.039), major liver injury (grades 4 and 5; p = 0.007), multiple CMEs at angiography (p = 0.031), incomplete TAE (p = 0.002), and elevated heart rate (p = 0.026). Incomplete embolization (OR = 8; p = 0.042), and heart rate >110 beats/min (bpm; OR = 8; p = 0.05) were independent factors for early failure of TAE in the group with major liver injuries. CONCLUSION: Major hepatic injury is an important factor in early failure. Patients with a heart rate >110 bpm and incomplete embolization in the major injury group have an increased rate of early failure. The success rate of proximal TAE was comparable to that of the more time-consuming, superselective, distal TAE.


Asunto(s)
Embolización Terapéutica/métodos , Hemorragia/terapia , Hígado/lesiones , Heridas no Penetrantes/diagnóstico por imagen , Heridas no Penetrantes/terapia , Adolescente , Adulto , Niño , Medios de Contraste , Extravasación de Materiales Terapéuticos y Diagnósticos/diagnóstico por imagen , Femenino , Frecuencia Cardíaca/fisiología , Hemorragia/diagnóstico por imagen , Hemorragia/etiología , Humanos , Hígado/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Intensificación de Imagen Radiográfica/métodos , Retratamiento/métodos , Retratamiento/estadística & datos numéricos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X/métodos , Insuficiencia del Tratamiento , Heridas no Penetrantes/complicaciones , Adulto Joven
19.
J Arthroplasty ; 29(12): 2439-46, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25047458

RESUMEN

Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P=1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P=1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.


Asunto(s)
Artroplastia de Reemplazo de Cadera/efectos adversos , Inhibidores del Factor Xa/administración & dosificación , Piridinas/administración & dosificación , Tiazoles/administración & dosificación , Tromboembolia Venosa/prevención & control , Trombosis de la Vena/prevención & control , Anciano , Antitrombinas/administración & dosificación , Método Doble Ciego , Enoxaparina/administración & dosificación , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Taiwán , Resultado del Tratamiento , Tromboembolia Venosa/etiología , Trombosis de la Vena/etiología
20.
Int J Clin Pract ; 67(4): 356-62, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23409734

RESUMEN

AIMS: Increasing evidence has proposed the components of metabolic syndrome (MtS) as risk factors for the development of benign prostate hyperplasia (BPH); therefore, it is thought that MtS may play a role in lower urinary tract symptoms related to BPH (BPH/LUTS) aetiology. Considering the closed relationships between MtS and BPH/LUTS, it is possible that patients with MtS might have different drug responsiveness in men with BPH/LUTS. We prospectively investigated the impact of MtS on responsiveness to α1-blocker in men with BPH/LUTS. METHODS: We enrolled a total of 109 patients with a mean (SD) age of 59.8 (9.0) years, having a prostate volume of 20 cm(3) or greater with moderate to severe LUTS. All patients received doxazosin GITS (gastrointestinal therapeutic system) 4 mg once daily for a 12-week period of treatment. The efficacy measurement was assessed by the changes from baseline in the total IPSS, maximum urinary flow rate and postvoid residual urine volume. The drug responders were defined as those who had a total IPSS decrease of more than 4 points from baseline after 12 weeks of treatment. RESULTS: Using multiple logistic regression analysis, our results showed that MtS was an independent factor for drug non-responder (OR = 4.26, p = 0.002). The rate of drug responder and total IPSS improvements in patients with MtS significantly decreased as the number of MtS components increased (p = 0.012 and p = 0.026). Among the MtS components, abnormal fasting blood glucose (FBG) was the most significantly independent factor for drug non-responder (OR = 3.17, p = 0.020). CONCLUSION: This study suggested that the presence of MtS had a significantly negative impact on the responsiveness to α1-blocker in men with BPH/LUTS. Our results are important for BPH/LUTS patients who did not initially respond to α1-blocker or who strive to reduce these metabolic risk factors.


Asunto(s)
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapéutico , Doxazosina/uso terapéutico , Síntomas del Sistema Urinario Inferior/tratamiento farmacológico , Síndrome Metabólico/complicaciones , Hiperplasia Prostática/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Síntomas del Sistema Urinario Inferior/complicaciones , Masculino , Persona de Mediana Edad , Hiperplasia Prostática/complicaciones , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...